Bicara Therapeutics Inc. Common Stock BCAX
$9.76
-44.16%
at last close
Analyst Consensus
- Consensus Rating
- Moderate Buy (8 Buy · 3 Hold · 0 Sell)
- Average Price Target
- $32.64
- Implied Upside
- +234.4%
- Price Target Range
- $20.00 – $42.00
- Analysts (12 mo)
- 11
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-10-19 | BTIGJeet Mukherjee |
Reiterates | Buy | $39 |
| 2026-08-19 | BMO CapitalDavid Lebowitz |
Initiates coverage on | Outperform | $35 |
| 2026-08-12 | Goldman Sachs Richard Law |
Maintains | Neutral | $18 → $20 |
| 2026-08-12 | WedbushDavid Nierengarten |
Maintains | Outperform | $30 → $33 |
| 2026-08-12 | Morgan StanleyJudah Frommer |
Maintains | Overweight | $37 → $39 |
| 2026-08-12 | MizuhoJoseph Catanzaro |
Maintains | Neutral | $18 → $20 |
| 2026-08-12 | Wells FargoEva Fortea Verdejo |
Maintains | Equal-weight | $16 → $23 |
| 2026-08-12 | BTIGJeet Mukherjee |
Maintains | Buy | $28 → $39 |
| 2026-05-12 | Goldman Sachs Richard Law |
Maintains | Neutral | $16 → $18 |
| 2026-05-12 | Morgan StanleyJudah Frommer |
Maintains | Overweight | $36 → $37 |
| 2026-05-11 | GuggenheimBrad Canino |
Initiates coverage on | Buy | $42 |
| 2026-03-31 | Goldman Sachs Richard Law |
Maintains | Neutral | $14 → $16 |
| 2026-03-31 | WedbushDavid Nierengarten |
Reiterates | Outperform | $30 |
| 2026-03-31 | Wells FargoEva Fortea Verdejo |
Maintains | Equal-weight | $11 → $16 |
| 2026-03-31 | CitizensReni J. Benjamin |
Reiterates | Market outperform | $31 |
| 2026-03-31 | HC Wainwright & Co.Robert Burns |
Maintains | Buy | $40 → $42 |
| 2026-03-25 | B of A SecuritiesTazeen Ahmad |
Initiates coverage on | Buy | $35 |
| 2026-01-29 | CitizensReni J. Benjamin |
Initiates coverage on | Market outperform | $31 |
| 2026-01-13 | WedbushDavid Nierengarten |
Reiterates | Outperform | $30 |
| 2026-01-08 | BTIGJeet Mukherjee |
Initiates coverage on | Buy | $28 |
| 2025-12-18 | MizuhoJoseph Catanzaro |
Initiates coverage on | Neutral | $18 |
| 2025-11-11 | Wells FargoEva Fortea Verdejo |
Maintains | Equal-weight | $8 → $11 |
| 2025-08-22 | HC Wainwright & Co.Robert Burns |
Maintains | Buy | $41 → $40 |
| 2025-08-19 | Piper SandlerKelsey Goodwin |
Initiates coverage on | Overweight | $36 |
| 2025-05-23 | Wells FargoEva Fortea Verdejo |
Upgrades | Underweight → Equal-weight | $8 |
| 2025-05-16 | HC Wainwright & Co.Robert Burns |
Maintains | Buy | $44 → $41 |
| 2025-04-17 | Wells FargoEva Fortea Verdejo |
Initiates coverage on | Underweight | $8 |
| 2025-04-07 | HC Wainwright & Co.Robert Burns |
Maintains | Buy | $45 → $44 |
| 2025-03-13 | Cantor FitzgeraldEric Schmidt |
Reiterates | Overweight | $13 |
| 2025-02-12 | WedbushDavid Nierengarten |
Reiterates | Outperform | $31 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $9.76
- Market Cap
- $1.16 billion
- 52-Week Range
- $8.90 – $30.99
- Average Volume
- 1.30 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.